Emerging drugs for the treatment of obesity

Expert Opinion on Emerging Drugs

Volumn 22, Issue 1, 2017, Pages 87-99

  Martinussen, Christoffer ^a,b   Bojsen Moller, Kirstine Nyvold ^a   Svane, Maria Saur ^a   Dejgaard, Thomas Fremming ^a,c   Madsbad, Sten ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

Author keywords

antiobesity drugs; appetite inhibition; Energy homeostasis; weight loss

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMYLIN; ANGIOGENESIS INHIBITOR; ANTIOBESITY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ESTERASE INHIBITOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; LEPTIN; LIRAGLUTIDE; LORCASERIN; MATRIX METALLOPROTEINASE INHIBITOR; MELANOCORTIN RECEPTOR AGONIST; METHIONYL AMINOPEPTIDASE 2; MONOAMINE; NEUROTRANSMITTER; PEPTIDE YY; PHENTERMINE PLUS TOPIRAMATE; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT;

APPETITE; BARIATRIC SURGERY; BODY WEIGHT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DRUG SAFETY; ENERGY BALANCE; HOMEOSTASIS; HUMAN; OBESITY; REVIEW; WEIGHT REDUCTION; ANIMAL; COMBINATION DRUG THERAPY; DRUG DESIGN; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; TIME FACTOR;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; MOLECULAR TARGETED THERAPY; OBESITY; TIME FACTORS; WEIGHT LOSS;

EID: 85014668396     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1080/14728214.2017.1269744     Document Type: Review

References (100)

1. Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet (London, England). 2011;378(9793):815–825.• A quick and well-illustrated overview using a simulation model to project the probable health and economic consequences of obesity in the next two decades.
2. Terranova L, Busetto L, Vestri A, et al. Bariatric surgery:cost-effectiveness and budget impact. Obes Surg. 2012;22(4):646–653.
3. Obesity and overweight. WHO (World Health Organization); 2016 [cited 2016 Jul14]. Available from:http://www.who.int/mediacentre/factsheets/fs311/en/
4. Simmonds M, Llewellyn A, Owen CG, et al. Predicting adult obesity from childhood obesity:a systematic review and meta-analysis. Obes Rev. 2016;17(2):95–107.
5. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.
6. Kolotkin RL, Meter K, Williams GR., Quality of life and obesity. Obes Rev. 2001;2(4):219–229.
7. Simpson KA, Martin NM, Bloom SR. Hypothalamic regulation of appetite. Expert Rev Endocrinol Metab. 2008;3(5):577–592.• Comprehensive evaluation of the physiological pathways and molecular mechanisms in appetite regulation.
8. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature. 2006;444(7121):854–859.
9. Ahima RS, Antwi DA. Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am. 2008;37(4):811–823.
10. Kim GW, Lin JE, Blomain ES, et al. Antiobesity pharmacotherapy:new drugs and emerging targets. Clin Pharmacol Ther. 2014;95(1):53–66.
11. Jones BJ, Bloom SR. The new era of drug therapy for obesity:the evidence and the expectations. Drugs. 2015;75(9):935–945.
12. Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond). 2013 Sep;37(9):1161–1168.
13. Troke RC, Tan TM, Bloom SR. The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis. 2014;5(1):4–14.
14. Münzberg H, Qualls-Creekmore E, Berthoud H-R, et al. Neural control of energy expenditure. Handb Exp Pharmacol. 2016;233:173–194.
15. Leibel RL, Seeley RJ, Darsow T, et al. Biologic responses to weight loss and weight regain:report from an American Diabetes Association research symposium. Diabetes. 2015 Jul;64(7):2299–2309.
16. Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond). 2010;34(Suppl 1(0 1)):S47–55.
17. Rosenbaum M, Leibel RL. 20 years of leptin:role of leptin in energy homeostasis in humans. J Endocrinol. 2014;223(1):T83–96.
18. MacLean PS, Higgins JA, Giles ED, et al. The role for adipose tissue in weight regain after weight loss. Obes Rev. 2015;16(Suppl 1):45–54.
19. Reinhardt M, Thearle MS, Ibrahim M, et al. A human thrifty phenotype associated with less weight loss during caloric restriction. Diabetes. 2015;64(8):2859–2867.
20. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604.
21. Krentz AJ, Fujioka K, Hompesch M. Evolution of pharmacological obesity treatments:focus on adverse side-effect profiles. Diabetes Obes Metab. 2016;18(6):558–570.
22. Derosa G, Maffioli P. Anti-obesity drugs:a review about their effects and their safety. Expert Opin Drug Saf. 2012;11(3):459–471.
23. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51(5):595–601.
24. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine–phentermine. N Engl J Med. 1997;337(9):581–588.
25. Rodgers RJ, Tschöp MH, Wilding JPH. Anti-obesity drugs:past, present and future. Dis Model Mech. 2012;5(5):621–626.
26. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917.• Evidence for increased risk of adverse cardiovascular outcome in patients randomized to sibutramine. The finding led to its withdrawal from the market.
27. Kirkham TC. Cannabinoids and appetite:food craving and food pleasure. Int Rev Psychiatry. 2009;21(2):163–171.
28. Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013;23(17):4751–4760.
29. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369(2):145–154.•• A multicenter randomized controlled trial of 5145 overweight or obese patients with type 2 diabetes followed for 10 years. Surprisingly, intentional weight loss did not improve cardiovascular outcome.
30. Kritchevsky SB, Beavers KM, Miller ME, et al. Intentional weight loss and all-cause mortality:a meta-analysis of randomized clinical trials. PLoS One. 2015;10(3):e0121993.
31. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention:the look AHEAD study. Obesity (Silver Spring). 2014;22(1):5–13.
32. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA. 2016;315(22):2424.• A recently published systematic review comparing efficacy and adverse events among the existing antiobesity drugs.
33. Dalle Grave R, Calugi S, Molinari E, et al. Weight loss expectations in obese patients and treatment attrition:an observational multicenter study. Obes Res. 2005;13(11):1961–1969.
34. Fildes A, Charlton J, Rudisill C, et al. Probability of an obese person attaining normal body weight:cohort study using electronic health records. Am J Public Health. 2015;105(9):e54–9.
35. Sjöström L. Review of the key results from the Swedish obese subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–234.•• Evidence for reduced mortality and morbidity following bariatric surgery. The first long-term, prospective, controlled trial investigating the effects of bariatric surgery on diabetes, cardiovascular disease events, cancer, and overall mortality.
36. Wolfe BM, Kvach E, Eckel RH. Treatment of obesity. Circ Res. 2016;118(11):1844–1855.
37. Tack J, Deloose E. Complications of bariatric surgery:dumping syndrome, reflux and vitamin deficiencies. Best Pract Res Clin Gastroenterol. 2014;28(4):741–749.
38. Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016;387(10031):1947–1956.
39. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–424.
40. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study:a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161.
41. Jacob S, Rabbia M, Meier MK, et al. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11(4):361–371.
42. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013 Jul;6(4):560–567.
43. Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors:a randomized clinical trial. JAMA. 2016;315(10):990–1004.
44. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes:the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699.•• Multinational randomized controlled trial providing evidence for liraglutide as a treatment for obesity.
45. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.•• Large-scale randomized controlled trial showing improved cardiovascular outcome for liraglutide compared with placebo. This has not been demonstrated for any other available antiobesity drug.
46. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med:Published Online. 2016 Sep 15. DOI:10.1056/NEJMoa1607141.•• Randomized controlled trial in 3297 adults with type 2 diabetes at high cardiovascular risk. Semaglutide reduced the risk of major cardiovascular events by 26% versus placebo.
47. Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond). 2013;37(11):1452–1459.
48. Le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246(5):780–785.
49. De Hollanda A, Jiménez A, Corcelles R, et al. Gastrointestinal hormones and weight loss response after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2014;10(5):814–819.
50. Tschöp MH, Finan B, Clemmensen C, et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 2016;24(1):51–62.
51. Miras AD, Le Roux CW. Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Int J Obes (Lond). 2014;38(3):325–333.
52. Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol. 2013;9(7):425–433.
53. Araujo F, Shrestha N, Granja PL, et al. Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects. Curr Pharm Biotechnol. 2014;15(7):609–619.
54. Davies M, Pieber TR, Jabbour S, et al. Dose-dependent glucose lowering and body weight reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes. EASD Annu Meet 2016;Abstract 149 [cited 2016 Sep19]. Available from:http://www.easdvirtualmeeting.org/resources/dose-dependent-glucose-lowering-and-body-weight-reductions-with-the-novel-oral-formulation-of-semaglutide-in-patients-with-early-type-2-diabetes
55. Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects:energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther. 2009;86(6):659–666.
56. Citeline’s Pharmaprojects, 2016.[cited 2016 Jun15]. Available from:https://pipeline.citeline.com/CpLogin.aspx
57. Orphan drug designations and approvals. U.S. Food and Drug Administration, 2016 [cited 2016 Aug3]. Available from:https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
58. Erondu N, Wadden T, Gantz I, et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring). 2007;15(4):895–905.
59. Omori N, Kouyama N, Yukimasa A, et al. Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist. Bioorg Med Chem Lett. 2012;22(5):2020–2023.
60. Poulton AS, Hibbert EJ, Champion BL, et al. Stimulants for the control of hedonic appetite. Front Pharmacol. 2016;7:105.
61. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients:a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2008;372(9653):1906–1913.•• Evidence that tesofensine produces a weight loss twice that of currently approved antiobesity drugs.
62. Gilbert J-A, Gasteyger C, Raben A, et al. The effect of tesofensine on appetite sensations. Obesity (Silver Spring). 2012;20(3):553–561.
63. Astrup A, Madsbad S, Breum L, et al. Under-reporting of adverse effects of tesofensine. Lancet (London, England). 2013;382(9887):127.
64. Frost A, Wishful shrinking:is the pipeline for obesity therapies set to expand with waistlines? Citeline, 2015 [cited 2016 Aug3]. Available from:https://citeline.com/wp-content/uploads/Citeline_Obesity_Whitepaper_V2_Final.pdf
65. Kopelman P, Groot GDH, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics:comparison with orlistat (Xenical). Obesity (Silver Spring). 2010 Jan;18(1):108–115.
66. Boston therapeutics announces FDA acceptance of IND to initiate a clinical trial of BTI-320 to treat type ll diabetes and weight loss. Boston Therapeutics Inc. 2014 [cited 2016 Aug3]. Available from:http://www.bostonti.com/news/press-releases/detail/814/boston-therapeutics-announces-fda-acceptance-of-ind-to
67. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion:results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154–2161.
68. Stenlöf K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382.
69. Erondu N, Hollander PA, Bays H, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese adults. EASD Annu Meet 2016;Abstract 76 [cited 2016 Sep15]. Available from:http://www.easdvirtualmeeting.org/resources/coadministration-of-canagliflozin-and-phentermine-for-weight-management-in-overweight-and-obese-adults
70. Dangerous gamble with a new class of diabetes drugs. ISMP QuarterWatch Annual Report, 2016; [cited 2016 Aug23] data from 2015 Q4. Available from:https://www.ismp.org/quarterwatch/pdfs/2015Q4.pdf
71. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.• Study of 7020 patients with type 2 diabetes. Evidence for a cardio- and kidney-protective effect of the SGLT-2 inhibitor empagliflozin.
72. Joharapurkar AA, Dhanesha NA, Jain MR. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes Metab Syndr Obes. 2014;7:73–84.
73. Zafgen announces beloranib IND placed on complete clinical hold. Zafgen Inc., 2015; [cited 2016 Aug3]. Available from:http://ir.zafgen.com/releasedetail.cfm?ReleaseID=945314
74. Beloranib demonstrates statistically and clinically significant improvements in body weight, body composition, and glycemic control in ZAF-203 clinical trial. Zafgen Inc., 2016; [cited 2016 Aug3]. Available from:http://ir.zafgen.com/releasedetail.cfm?ReleaseID=975343
75. Zafgen refocuses resources on development of differentiated second-generation MetAP2 inhibitor ZGN-1061. Zafgen Inc, 2016; [cited 2016 Aug3]. Available from:http://ir.zafgen.com/releasedetail.cfm?ReleaseID=980192
76. Jaoude J, Koh Y. Matrix metalloproteinases in exercise and obesity. Vasc Health Risk Manag. 2016;12:287–295.
77. Okauchi Y, Nishizawa H, Funahashi T, et al. Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men. Diabetes Care. 2007;30(9):2392–2394.
78. Pioneer in the Angiogenesis Biotech Industry. AngioLab Inc., 2016; [cited 2016 Aug3]. Available from:http://www.angiolab.co.kr/html/product_02e.php
79. Slentz CA, Aiken LB, Houmard JA, et al. Inactivity, exercise, and visceral fat. STRRIDE:a randomized, controlled study of exercise intensity and amount. J Appl Physiol. 2005;99(4):1613–1618.
80. Yu XX, Watts LM, Manchem VP, et al. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PLoS One. 2013;8(7):e66923.
81. Pipeline. Ionis Pharmaceuticals, 2016; [cited 2016 Aug3]. Available from:http://www.ionispharma.com/pipeline/
82. Hardie DG. AMPK:a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond). 2008;32(Suppl 4):S7–12.
83. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612–622.
84. LIPO-202. Neothetics Inc., 2016; [cited 2016 Aug3]. Available from:http://neothetics.com/lipo.html
85. Svane MS, Jørgensen NB, Bojsen-Møller KN, et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. Int J Obes (Lond). 2016:cited 30August 2016. DOI:10.1038/ijo.2016.121
86. Vilsbøll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss:systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.• Systematic review and meta-analyses providing evidence that GLP-1 agonists produce weight loss in overweight and obese patients with or without type 2 diabetes.
87. Blundell J, Finlayson G, Axelsen M, et al. Semaglutide reduces appetite and energy intake, improves control of eating, and provides weight loss in subjects with obesity. Diabetes. 2016;65(supl1):abstract 23–OR.cited 2016 Aug4. Available from:http://www.abstractsonline.com/pp8/#!/4008/presentation/43943
88. Baron MA, Denham D, Prabhakar P, et al. Efficacy and tolerability of ITCA 650 versus sitagliptin in uncontrolled type 2 diabetes patients on metformin monotherapy:results of the FREEDOM-2 study. EASD Annu Meet 2016;Abstract 150.[cited 2016 Sep19]. Available from:http://www.easdvirtualmeeting.org/resources/efficacy-and-tolerability-of-itca-650-versus-sitagliptin-in-uncontrolled-type-2-diabetes-patients-on-metformin-monotherapy-results-of-the-freedom-2-study
89. Smith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816–1823.
90. Campbell JE, Drucker DJ. Islet α cells and glucagon–critical regulators of energy homeostasis. Nat Rev Endocrinol. 2015;11(6):329–338.
91. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27–36.•• The first study to discover a triagonist molecule that effectively reduces bodyweight in obese rodents.
92. Vorobiev I, Matskevich V, Kovnir S, et al. Chemical polysialylation:design of conjugated human oxyntomodulin with a prolonged anorexic effect in vivo. Biochimie. 2013;95(2):264–270.
93. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin:an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring). 2009;17(9):1736–1743.• Evidence that leptin responsiveness in obesity may be, at least partially, restored.
94. Amylin and Takeda voluntarily suspend clinical activities in obesity trial. Takeda Pharmaceutical Company Limited, 2011; [cited 2016 Aug3]. Available from:https://www.takeda.com/news/2011/20110317_3836.html
95. Amylin and Takeda discontinue development of pramlintide/metreleptin combination treatment for obesity following commercial reassessment of the program. Takeda Pharmaceutical Company Limited, 2011; [cited 2016 Aug3]. Available from:http://www.takeda.com/news/2011/20110805_3889.html
96. Müller TD, Sullivan LM, Habegger K, et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci. 2012;18(6):383–393.
97. Clemmensen C, Chabenne J, Finan B, et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes. 2014;63(4):1422–1427.
98. Wewer Albrechtsen NJ, Hornburg D, Albrechtsen R, et al. Oxyntomodulin identified as a marker of type 2 diabetes and gastric bypass surgery by mass-spectrometry based profiling of human plasma. EBioMedicine. 2016;7:112–120.
99. Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22(7):1084–1096.
100. Nishizawa M, Nakabayashi H, Uehara K, et al. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. Am J Physiol Endocrinol Metab. 2013;305(3):E376–87.